Klinik Favoriten — Clinical Trial Site

18 Registered trials

11 Currently recruiting

Organisation

Klinik Favoriten

Location

Vienna, Austria

Identifier

ORG-100040139

Address

Kundratstrasse 3, Favoriten, 1100, Austria

Departments

104007: "3. Medizinische Abteilung Zentrum für Onkologie und Hämatologie"
5. Medizinische Abteilung Kardiologie
5. Medizinische Abteilung mit Kardiologie
5th Medical Department Divison of Cardiology
5th Medical Department with Cardiology
5th Medical Department/Cardiology
Cardiology
Chirurgie
Department of Cardiology
Department of Internal Medicine
Department of Internal Medicine IV, Division of Infectious Diseases and Tropical Medicine
Department of Surgery Heopato-Pancreato-Billary Center
Dept Sugery
Internal Medicine V, Cardiology
Klinische Abteilung für Kardiologie
Medizinische Abteilung - Kardiologie
Surgical Department

Clinical trials at this site (18)

Search interface

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending

2025-522475-28-00 Pulmonary Hypertension (PH) with Heart Failure with pre 5
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Newly Diagnosed AML with an NPM1 mutation 5 2026-04-02
A study to learn more about the change in the blood levels of transthyretin when participants with transthyretin amyloidosis with cardiomyop… Recruiting

2025-521831-35-00 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) 6 2026-02-12
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Recruiting

2024-519917-72-00 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amy 5 2025-10-29
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The… Recruiting

2024-511950-35-00 Acute Myocardial Infarction 5 2025-06-12
A Phase 3 efficacy and safety study of fosmanogepix for the treatment of adult participants with candidemia and/or invasive candidiasis. Recruiting

2022-500455-23-00 Candidemia 5 2024-12-11
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on… Recruiting

2022-502135-19-00 Calcific Aortic Valve Stenosis 4 2024-07-18
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
Effect of high-dose vitamin D on 28-day mortality in adult critically ill patients with severe vitamin D deficiency Recruiting

2024-514556-32-00 Adult critically ill patients with severe vitamin D def 5 2017-02-15
A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously … Ended

2023-503229-21-00 Unresectable hepatocellular carcinoma (HCC) 5 2021-05-06
A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Res… Ended

2023-508726-10-00 Hepatocellular Carcinoma 5 2018-03-28
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and … Ended

2024-517340-61-00 Patients after curative intent resection of cholangioca 5 2024-11-19
A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular C… Ended

2022-502840-11-00 Hepatocellular Carcinoma (Morpheus-Neo HCC) 9 2023-11-28
A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and… Ended

2022-502382-25-00 Heart Failure and Pulmonary Hypertension due to Left He 4 2023-08-24
Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended

2022-502316-36-00 Symptomatic Obstructive Hypertrophic Cardiomyopathy 11